MannKind saw the highest growth of 3.99% in patent filings and 1.49% in grants in June in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 1.99% and grants by 0.99%. GlobalData’s DataBook provides a comprehensive analysis of MannKind‘s patent filings and grants. Buy the databook here.
MannKind has been focused on protecting inventions in United States(US) with ten publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 43% filings and 57% grants. The United States(US), Australia(AU), Israel(IL), and China(CN) patent Office are among the top ten patent offices where MannKind is filings its patents. Among the top granted patent authorities, MannKind has 57% of its grants in United States(US), 14% in Australia(AU) and 14% in Israel(IL).
Philip Morris International could be the strongest competitor for MannKind
MannKind stands in second position with respect to its patent publications among its competitors.
Patents related to rare diseases and climate change lead MannKind's portfolio
MannKind has the highest number of patents in rare diseases followed by, climate change and healthtech. For rare diseases, nearly 40% of patents were filed and no patents were granted in Q2 2024.
Diabetes related patents lead MannKind portfolio followed by pulmonary hypertension, and hypertension
MannKind has highest number of patents in diabetes followed by pulmonary hypertension, hypertension, obesity, and inflammation. For diabetes, nearly 8% of patents were filed and 12% of patents were granted in Q2 2024.
For comprehensive analysis of MannKind's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.